located on chromosome 12p13. These microRNAs display marked structural similarities, suggesting that they mainly target the same genes. The wide variety of microRNA targets make them interesting as potential contributors to the plasticity of processes involved in epithelial-mesenchymal transition (EMT) and metastasis [8] . So, the goal of this study is to identify patterns of miRNA-200b deregulation and its prognostic role in breast cancer.
Material and Methods:
Forty eight cases of female invasive duct carcinoma and fourteen control cases of adjacent normal breast tissue from the same malignant cases were included in this study. Cases were obtained from the registry of the pathology department at South Egypt Cancer Institute. All the specimens were preserved and fixed in 10% buffered formalin, processed as usual then paraffin embedded.
Clinical and pathological data were collected from the registry. These data include patient's age, occurrence of metastasis or recurrence, size of the primary breast mass, vascular invasion, regional lymph nodes status and the status of estrogen and progesterone receptors expression condition in the tumor cells.
All tissue samples were subjected to the measurement of the expression of micro RNA (200b) via quantitative real -time PCR technique: RNA extraction was done using miRNAeasy FFPE kit (catalog no 73504) designed for total RNA extraction including miRNA from formalin fixed, paraffin embedded (FFPE) tissue sections. After that samples were processed by 2 step PCR reaction where cDNA synthesis were done using Taqman®microRNA Reverse transcription kit (Catalog No. 4366596) with a total reaction volume 15 ul (7ul master mix + 3ul RT primers + 5 ul RNA). The primer used is a small RNA specific stem loop RT primer.
qPCR reaction
quantitative PCR reaction was done using Taqman®ssay in 20 ul reaction (10 ul Taqman® universal PCR master mix II (2X) + 3 ul c DNA + 6 ul nuclease free water + 1 ul Taqman® small RNA assay, life technologies (Inventoried Cat # 4427975). Reaction mix loaded to the Applied Biosystem 7500 instrument, life technologies, USA (Catalog No.4366855) .
Cycling program as follow; 50 ͦ c: 2 minutes, 95 ͦ c: 10 minutes and 40 cycles (95 ͦ c: 15 seconds, 60 ͦ c: 60 seconds).
Data Analysis
Relative quantification was done using the comparative CT (∆∆CT) method. The over or down expression were estimated as folds of rise or decrease in gene expression of the target cases (normalized ratio) in comparison to the calibrator cases (normalized ratio) using the ∆∆CT method calculation by Applied Biosystem detection software.
Statistical Analysis:
Data was entered on a PC using Microsoft Excel 2013 (Microsoft Corporation). Data then was analyzed using SPSS version 21 (IBM Corporation). Data was described as number and percentage for categorical data. For quantitative data, it was described using mean and standard deviation for normally distributed data and median and interquartile range (IQR) for those not normally distributed.
To evaluate difference between groups, the following tests were used; Chi square for categorical data, Student t-test for normally distributed quantitative data and Mann Whitney U test and Kruskal Wallis for not normally distributed quantitative data. Correlation was done for quantitative data using Pearson´s correlation for normally distributed data and Spearman´s correlation for those not normally distributed. P value was considered significant if it is equal to or less than 0.05.
Overall survival and disease free survival were done by using Kaplan-Meier method. The end point for overall survival was death and for disease free survival was relapse. Significance test was done by using Log Rank (Mantel-Cox).
Results:
Our study included 48 female patients, all were diagnosed as breast cancer (IDC). Their mean ages were 53.5± 13.57 years, ranging from 28 to 80 years. 24 patients (50%) were postmenopausal. Concerning tumor characteristics, 28 (58.3%) patients had tumor size ≥2 cm and <5 cm and 18 (37.5%) had tumor ≥ 5 cm. Histologic grade II was reported in 40 patients (88.3%).Estrogen receptors expression in the cells was detected in 27 (56.3%) of the samples while progesterone receptors expression was detected in 25 (52.1%) samples .Lymph node metastasis was detected in 36 (75%) patients while vascular invasion occurred in 38 (79.2%) patients. Distant metastasis was detected in 8 (16.7 %) patients (Table 1) . miR-200b expression in both cancerous and adjacent normal tissue samples are shown in (Table 2) . Among cancerous tissue samples, miR-200b over expression was showed in 36 (75%) samples while down regulation was detected in 12 (25%) samples. In contrary, among non cancerous tissue samples, miR200b over expression was detected in 13 (92.2%) samples while down regulation was detected in 1 (7.1%) sample only. These differences were highly significant (P =<0.001).
As regard to the relative quantity (RQ) of miR200b, there was highly significant down regulation of miR-200b in the malignant group in comparison to the control group, median (IQR) = 0.152 (1.208) and 1.000 (0.000), respectively) (P=0.005) as shown in Table ( Breast cancer is the most frequent carcinoma and the second most common cause of cancer-related mortality in women [19] . Also, Iorio and colleagues [20] identified a global pattern of miRNA deregulation in breast cancer tissue when compared with normal breast tissue, hinting at the importance of miRNA deregulation in the development of breast cancer in general.
As miRNAs appear to be critical regulators of tumor biology, their potential as prognostic and predictive biomarkers has recently been given attention. In addition, their great stability when compared with mRNA molecules, both in blood samples and in formalin-fixed, paraffin-embedded tissue samples, offers a great advantage [21, 22] .
In this study, we investigated the expression of miR-200b and its prognostic role in breast cancer in 48 female patients, all were diagnosed with breast cancer (IDC). The expression of miR-200b in both cancerous and adjacent normal tissue samples showed over expression of miRNA in 13 (92 .2%) of normal tissue samples in comparison to 12 (25 %) of cancerous samples. Down expression of miR-200b was showed in 36 (75%) cancerous samples while it was reported in 1 (7.1%) normal sample only. These differences were highly significant (P=<0.001).
As 
Conclusion:
In conclusion, our study demonstrated that miR200b could be a tumor suppressor and a potential biomarker in breast cancer patients. We hypothesize that such profiles of miR-200b expression can be informative for breast cancer detection and prognosis and might assist in defining specific targets for future therapy. 
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